论文部分内容阅读
为研究脑肠肽（Brain-Gut-Peptide，BGP）在结肠癌发生和发展中的调节作用，本研究测定了溃疡性结肠炎（UC）、癌前病变（PCL）和结肠癌（CC）各30例患者的血浆肽水平，并对其中11例癌术后和1例癌术后复发患者的血浆肽进行了复查。发现从UC、PCL到CC组，血浆生长抑素（SS）和血管活性肠肽（VIP）水平明显降低，而血浆胃动素（MTL）和P物质（SP）水平明显升高（P＜0．01或P＜0．05），而痛术后复发者血浆肽又恢复术前水平。上述结果支持BGP参与调节结肠癌发生和发展的平衡理论假说，高浓度的SS和VIP起抑癌作用，而高浓度的MTL和SP起促癌形成作用。通过调整BGP水平可用于结肠癌的治疗，通过检测结肠疾病患者的血浆BGP水平，将有助于结肠癌的诊断和癌切除效果及术后复发的判断。
To study the regulation of Brain-gut-Peptide (BGP) in the occurrence and development of colon cancer, the present study determined ulcerative colitis (UC), precancerous lesions (PCL), and colon cancer (CC). Plasma peptide levels were measured in 30 patients, and plasma peptides in 11 patients with cancer and 1 patient with cancer recurrence were reviewed. It was found that plasma levels of somatostatin (SS) and vasoactive intestinal peptide (VIP) were significantly lower in UC and PCL-CC groups, and plasma levels of motilin (MTL) and substance P (SP) were significantly higher (P<0). .01 or P<0.05), and plasma peptides relapsed after the onset of pain returned to preoperative levels. The above results support the hypothesis that BGP participates in the balance theory of regulating the occurrence and development of colon cancer. High concentrations of SS and VIP may play a role in suppressing cancer, while high concentrations of MTL and SP may play a role in promoting cancer formation. By adjusting BGP levels can be used for the treatment of colon cancer, by detecting plasma BGP levels in patients with colon disease, will help colon cancer diagnosis and cancer resection and postoperative recurrence judgments.